Loading...
XNAS
ADIL
Market cap7mUSD
Jul 22, Last price  
0.47USD
1D
-7.20%
1Q
-32.80%
IPO
-99.53%
Name

Adial Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
116.14%
Rev. gr., 5y
%
Revenues
0k
Net income
-13m
L+88.48%
-817,993-420,200-1,139,456-11,631,378-8,591,429-10,860,495-19,423,326-12,731,416-7,001,890-13,197,451
CFO
-7m
L+1.70%
-465,222-274,384-494,862-2,498,387-6,338,614-7,633,161-11,949,429-11,185,985-6,806,809-6,922,306
Earnings
Aug 11, 2025

Profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
IPO date
Jul 27, 2018
Employees
16
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
8,284
6,889
13,378
Unusual Expense (Income)
NOPBT
(8,284)
(6,889)
(13,378)
NOPBT Margin
Operating Taxes
(502)
Tax Rate
NOPAT
(8,284)
(6,889)
(13,377)
Net income
(13,197)
88.48%
(7,002)
-45.00%
(12,731)
-34.45%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,021
4,132
9,126
BB yield
-21.42%
-155.94%
-4,238.11%
Debt
Debt current
57
Long-term debt
358
Deferred revenue
Other long-term liabilities
(437)
492
Net debt
(4,732)
(4,361)
(2,986)
Cash flow
Cash from operating activities
(6,922)
(6,807)
(11,186)
CAPEX
Cash from investing activities
1,500
Cash from financing activities
7,846
4,132
9,126
FCF
(8,284)
(6,644)
(13,317)
Balance
Cash
3,751
2,827
4,002
Long term investments
982
1,534
(601)
Excess cash
4,732
4,361
3,401
Stockholders' equity
(81,989)
(68,796)
(63,648)
Invested Capital
86,057
72,879
67,624
ROIC
ROCE
EV
Common stock shares outstanding
18,589
1,425
40
Price
1.01
-45.70%
1.86
-65.40%
5.38
-92.04%
Market cap
18,775
608.51%
2,650
1,130.65%
215
-99.57%
EV
14,042
(1,711)
(2,771)
EBITDA
(8,284)
(6,888)
(13,317)
EV/EBITDA
0.25
0.21
Interest
585
Interest/NOPBT